Grail (NASDAQ:GRAL) Sets New 52-Week High – Here’s What Happened

Grail, Inc. (NASDAQ:GRAL)’s share price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $23.71 and last traded at $23.21, with a volume of 300071 shares. The stock had previously closed at $22.16.

Analyst Upgrades and Downgrades

GRAL has been the subject of several research reports. Wolfe Research began coverage on shares of Grail in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Guggenheim began coverage on Grail in a research report on Thursday, October 17th. They issued a “neutral” rating on the stock. Finally, Morgan Stanley assumed coverage on Grail in a research report on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 price objective for the company.

Grail Trading Down 23.4 %

The firm has a 50-day simple moving average of $16.27.

Insiders Place Their Bets

In other news, CEO Robert P. Ragusa sold 123,454 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total value of $1,730,825.08. Following the completion of the sale, the chief executive officer now directly owns 612,661 shares of the company’s stock, valued at approximately $8,589,507.22. The trade was a 16.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Aaron Freidin sold 30,452 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $14.02, for a total value of $426,937.04. Following the transaction, the chief financial officer now owns 268,277 shares in the company, valued at $3,761,243.54. This represents a 10.19 % decrease in their position. The disclosure for this sale can be found here. Insiders acquired 58,829 shares of company stock valued at $757,298 in the last ninety days.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.